Employers’ benefit coverage decisions and the impact those decisions have on the market for rare disease / orphan drugs are a growing concern for biopharma companies
Biopharma companies need to see the employer market clearly in the short and long-term to be able to understand payers management methods for orphan drugs and the impact those decisions will have on their drugs
Independence Blue Cross (Independence) recently announced the launch of its Advanced Network for Gene-Based Therapeutics, which will be effective March 1, 2023
Corcept Therapeutics Extends Exclusive Specialty Pharmacy Distribution Agreement for Korlym with Optime Care
AscellaHealth’s comprehensive portfolio of services results in streamlined access to therapy, optimal clinical results and an enhanced patient journey
QOL Medical Selects Optum Frontier Therapies as New Pharmacy Partner for Sucraid® to support CSID patients nationwide being treated with Sucraid® (sacrosidase) Oral Solution
This year, UBC has partnered with Seqster and acquired Marketshare Movers to advance the company’s capabilities in clinical trials and co-pay and affordability programs
Biologics by McKesson continues to solidify its leadership position a provider for limited and exclusive drugs in the specialty pharmacy market